Search - tctmd.com

Displaying 441 - 460 of 2782

Sort: Relevancy | Date

In the US, COVID Reversed CV Mortality Gains, Hitting Black Americans Hardest

News Daily News

In the US, COVID Reversed CV Mortality Gains, Hitting Black Americans Hardest

November 29, 2022

Slight Risk of Interstitial Lung Disease Seen With Certain DOACs

News Daily News

Slight Risk of Interstitial Lung Disease Seen With Certain DOACs

November 23, 2022

P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis

News Daily News

P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis

November 21, 2022

Left-Sided Bioprosthetic Valves Often Dysfunctional in Pregnant Women

News Daily News

Left-Sided Bioprosthetic Valves Often Dysfunctional in Pregnant Women

November 21, 2022

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

News Daily News

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

Yael L. Maxwell

November 21, 2022

Exposure to Lead Linked to Risk of CVD Mortality: Strong Heart Study

News Daily News

Exposure to Lead Linked to Risk of CVD Mortality: Strong Heart Study

Michael O'Riordan

November 18, 2022

Drug Preconditioning Before CABG, Valve Surgery Shows Promise: START

News Conference News AHA 2022

Drug Preconditioning Before CABG, Valve Surgery Shows Promise: START

November 14, 2022

Sizeable Minority of Pregnant Women Have CVD, US Data Show

News Conference News AHA 2022

Sizeable Minority of Pregnant Women Have CVD, US Data Show

November 11, 2022

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

News Conference News AHA 2022

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

Yael L. Maxwell

November 11, 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

News Conference News AHA 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

November 10, 2022

Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI

News Conference News AHA 2022

Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI

Yael L. Maxwell

November 10, 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

News Conference News AHA 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

November 06, 2022

IRONMAN Misses but Lends Support to IV Iron Repletion in HF

News Conference News AHA 2022

IRONMAN Misses but Lends Support to IV Iron Repletion in HF

November 05, 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

Renal Function Affects Ticagrelor/Aspirin Impact on Recurrent Stroke: CHANCE-2

News Daily News

Renal Function Affects Ticagrelor/Aspirin Impact on Recurrent Stroke: CHANCE-2

Yael L. Maxwell

November 03, 2022

Extreme BP-Lowering Harmful After Stroke Thrombectomy: ENCHANTED2/MT

News Daily News

Extreme BP-Lowering Harmful After Stroke Thrombectomy: ENCHANTED2/MT

November 01, 2022

Apixaban Again Linked to Less Bleeding in AF Patients

News Daily News

Apixaban Again Linked to Less Bleeding in AF Patients

Michael O'Riordan

October 31, 2022

Study Affirms Higher CVD, Mortality Risks Among COVID-Positive Patients

News Daily News

Study Affirms Higher CVD, Mortality Risks Among COVID-Positive Patients

October 26, 2022

New Biomarker-Based Risk Score Performs Well in ACS

News Daily News

New Biomarker-Based Risk Score Performs Well in ACS

Michael O'Riordan

October 25, 2022

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.